Baxter International Inc. (BAX)

Baxter International's stock price declined by 43.51% between September 27, 2024, and September 26, 2025. In Q2 2025, Baxter reported adjusted EPS of $0.59, in line with guidance but slightly missing estimates, with sales of $2.81 billion, up 4% year-over-year but missing consensus by $10 million. Baxter lowered its 2025 operational sales growth outlook from 4%-5% to 3%-4% and updated its full-year adjusted earnings guidance to $2.42-$2.52 per diluted share. The lowered guidance incorporated risks from a voluntary pause in shipments of the Novum LVP infusion pump and softness in demand for IV solutions due to fluid conservation efforts after Hurricane Helene. Stifel downgraded Baxter to Hold from Buy with a reduced price target. Andrew Hider was appointed as the new CEO.

Based on the available information, there is no explicit recurring seasonal demand pattern identified for Baxter International, Inc.'s products and services. Demand for certain products, such as IV solutions, can be impacted by unforeseen events like natural disasters, as seen with Hurricane Helene.

Baxter International, Inc. (BAX) is an American multinational healthcare company headquartered in Deerfield, Illinois, operating in the Medical Equipment industry. Baxter develops, manufactures, and commercializes healthcare products and digital health solutions for chronic and acute medical conditions. Its product portfolio includes medical products and therapies, healthcare systems and technologies, and pharmaceuticals, utilized in hospitals, nursing homes, and at-home care settings.

Baxter International, Inc. has a significant global presence with its headquarters in Deerfield, Illinois. The company manufactures products in over 20 countries and markets them in more than 100 countries across the Americas, the Middle East, Africa, Europe, and Asia-Pacific. In 2013, 42% of its sales were in the United States, 30% in Europe, 16% in Asia Pacific, and 12% in Latin America and Canada.

In September 2025, Baxter achieved a Gold Resiliency Badge for IV Solutions, Nutrition Solutions, and Premix Drugs from the Healthcare Industry Resilience Collaborative. Also in September 2025, Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor. Baxter voluntarily paused shipments of its Novum LVP infusion pump, focusing on supporting existing customers. The company experienced softness in demand for IV solutions due to fluid conservation efforts following Hurricane Helene.

Baxter International is predominantly owned by institutional shareholders, who hold 96.39% of the company, while insiders own 16.10% and retail investors hold 0.00%. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and Dodge & Cox. The largest individual shareholder is Third Point LLC, owning 76.86 million shares, representing 14.96% of the company.